Additionally, pbDMG patients with low levels of JAK1 or STAT1 mRNA expression in combination with high levels of TGFB2 exhibited poor OS outcomes, suggesting that stimulating and activating JAK1 and STAT1 in anti-tumor APC cells, using IFN-γ in the brainstem tumor microenvironment could enhance the effect of the TGFB2 blockade. The gene discussed is JAK1; the disease is neoplasm.